Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,166.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Up 0.7 %

United Therapeutics stock opened at $236.93 on Friday. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The stock has a market cap of $11.15 billion, a PE ratio of 11.94 and a beta of 0.52. The firm’s 50-day simple moving average is $231.20 and its 200 day simple moving average is $228.44. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.67 earnings per share. Research analysts predict that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in United Therapeutics by 5.4% in the first quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock valued at $1,064,249,000 after acquiring an additional 241,594 shares during the last quarter. Vanguard Group Inc. boosted its stake in United Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock valued at $1,053,212,000 after acquiring an additional 20,373 shares during the last quarter. State Street Corp boosted its stake in United Therapeutics by 4.5% in the second quarter. State Street Corp now owns 1,875,758 shares of the biotechnology company’s stock valued at $414,074,000 after acquiring an additional 80,656 shares during the last quarter. Wellington Management Group LLP boosted its stake in United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after acquiring an additional 710,668 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of United Therapeutics by 14.9% in the first quarter. Geode Capital Management LLC now owns 759,143 shares of the biotechnology company’s stock valued at $169,811,000 after purchasing an additional 98,267 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. Wedbush reiterated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. SVB Leerink initiated coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $213.00 to $215.00 in a report on Monday, February 12th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.67.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.